Breaking News, Financial News

Pfizer Revenues Soar to Record-Breaking $100B in 2022

Comirnaty and Paxlovid rake in $56.7 billion in 2022 while sales of these COVID products are expected to decline as much as 60% in 2023.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer 4Q Revenues: $24.3 billion (+2%) 4Q Earnings: $5.0 billion (+47%) YTD Revenues: $100.3 billion (+23%) YTD Earnings: $31.4 billion (+43%) Comments: Growth was primarily driven by Covid-19 products: Comirnaty sales were $11.3 billion in the quarter, down 9% and $37.8 billion for the year, up 3%. Paxlovid sales were $1.8 billion in the quarter and $18.9 billion for the year. Excluding contributions from Paxlovid and Comirnaty, revenues in the quarter grew $571 million, or 5%.   Primar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters